OBJECTIVE： To compare the economy of rabeprazole， pantoprazole and omeprazole in the treatment of peptic ulcer. METHODS： 189 patients with peptic ulcer admitted into our hospital during Jan.-Oct. in 2015 were divided into rabeprazole group （group A）， pantoprazole group （group B） and omeprazole group （group C） according to random number table， with 63 cases in each group. 3 groups received treatment for 4 weeks according to package inserts based on disease condition. Clinical effective rate， Hp clearance rate and the incidence of ADR were calculated， and the economy was evaluated. RESULTS： The effective rates of groups A， B and C were 79.4％， 81.0％ and 77.8％； Hp clearance rates were 85.7％， 85.7％ and 83.7％； the incidence of ADR were 11.1％， 12.7％ and 12.7％， without statistical significance （P＞0.05）， So cost-minimization analysis was used for economic evaluation. The costs of groups A， B and C were 704.08， 648.92， 611.96 yuan， and the descending order group A＞group B＞group C. Sensitivity analysis supported the result. CONCLUSIONS： Rabeprazole， pantoprazole and omeprazole show good therapy efficacy and safety in the treatment of peptic ulcer. Compared to rabeprazole and pantoprazole， omeprazole has lower cost and better economics in the treatment of peptic ulcer. The drugs should be chosen according to disease condition.